Full text is available at the source.
Abstract
Four cases of allodynia were reported in patients prescribed a 2.4-mg dose of the GLP-1 receptor agonist semaglutide.
- Allodynia, or skin pain to the touch, was observed in patients following dose escalation of semaglutide.
- Symptoms were noted specifically at the 2.4-mg subcutaneous once-weekly dosage.
- Two patients stopped therapy, resulting in resolution of their symptoms.
- One patient who continued treatment experienced symptom resolution after 4 months.
- A clear temporal and dose-response relationship was identified among the four cases.
- No pharmacological mechanism for this adverse reaction was determined.
Simplified